Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 53Prostate Cancer Metastatic 6Neoplasm Metastasis 6Carcinoma, Transitional Cell 4Neoplastic Cells, Circulating 3Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Thrombocytosis 1Testicular Neoplasms 1Prostate Cancer, Hereditary, 7 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer, MCRPC 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone-Resistant Prostate Cancer × cabazitaxel × Genitourinary × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡